Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Depreciation & Amortization (CF): 2012-2025

Historic Depreciation & Amortization (CF) for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $1.4 million.

  • Agios Pharmaceuticals' Depreciation & Amortization (CF) rose 2.16% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 7.22%. This contributed to the annual value of $5.7 million for FY2024, which is 14.65% down from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Depreciation & Amortization (CF) stood at $1.4 million, which was up 9.13% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $2.5 million in Q1 2021 and a low of $1.3 million during Q2 2025.
  • For the 3-year period, Agios Pharmaceuticals' Depreciation & Amortization (CF) averaged around $1.5 million, with its median value being $1.4 million (2025).
  • In the last 5 years, Agios Pharmaceuticals' Depreciation & Amortization (CF) declined by 27.76% in 2023 and then increased by 2.16% in 2025.
  • Agios Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $2.2 million in 2021, then declined by 17.62% to $1.8 million in 2022, then declined by 22.66% to $1.4 million in 2023, then fell by 2.57% to $1.4 million in 2024, then climbed by 2.16% to $1.4 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.4 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.3 million for Q1 2025.